Apollo Medical Holdings, Inc. Reports Fourth Quarter and Year-End 2022 Results

About this update from Astrana Health Inc.

[{"type":"text","content":"Company to Host Conference Call on Friday, Feb. 24, 2023, at 5:30 a.m. PT/8:30 a.m. ET \nALHAMBRA, Calif., Feb. 23, 2023 /PRNewswire/ -- Apollo Medical Holdings, Inc. (\"ApolloMed,\" and together with its subsidiaries and affiliated entities, the \"Company\") (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced its consolidated financial results for the fourth quarter and year ended December 31, 2022.\n\n \n \n \n \n \n \n\n \nFinancial Highlights for the Year Ended December 31, 2022:\nTotal revenue of $1.14 billion, an increase of 48% from $773.9 million for the prior yearNet income attributable to ApolloMed of $49.0 millionEarnings per share - diluted (\"EPS – diluted\") of $1.08Adjusted EBITDA of $140.0 million, an increase of 5%, compared to $133.5 million for the prior year, resulting in an Adjusted EBITDA margin of 12.2%(1)Cash and cash equivalents of $288.0 million at December 31, 2022(1) See \"Reconciliation of Net Income to EBITDA and Adjusted EBITDA\" and \"Use of Non-GAAP Financial Measures\" below for additional information.\nFinancial Highlights for Fourth Quarter 2022:\nTotal revenue of $294.2 million, an increase of 51% from $195.1 million for the prior-year quarterNet loss attributable to ApolloMed of $2.6 millionAdjusted EBITDA of $23.7 million, an increase of 54% from $15.4 million for the prior-year quarterGuidance:\nApolloMed is providing the following guidance for total revenue, net income, EBITDA, Adjusted EBITDA, and EPS - diluted. The net income and EBITDA guidance ranges below include the impact of the excluded assets held by Allied Physicians of California, a Professional Medical Corporation's (\"APC\"), which are solely for the benefit of APC and its shareholders. Any gains or losses associated with these excluded assets do not have an impact on Adjusted EBITDA and EPS - diluted. These guidance assumptions are based on the Company's existing business, current view of existing market conditions and assumptions for the year ending December 31, 2023.\n($ in millions)\n2023 Guidance Range\nLow\nHigh\nTotal revenue\n$ 1,300.0\n$ 1,500.0\nNet income\n$ 49.5\n$ 71.5\nEBITDA\n$ 89.5\n$ 129.5\nAdjusted EBITDA\n$ 120.0\n$ 160.0\nEPS – diluted\n$ 0.95\n$ 1.20\nSee \"Guidance Reconciliation o...

More updates from Astrana Health Inc.